Immunotherapy for HIV/AIDS

*Pharmaceutical Formulation Design - Recent Practices*

• HIV is localized in latent cellular and anatomical reservoirs where the majority of therapeutic agents are unable to completely eradicate the virus for the

• The anatomical reservoirs where the HIV get resides are CNS, the cerebrospinal fluid, the lymphatic system, tests, liver, kidney, lungs, the gut and in the

• Microphages act as host for viral genetic recombination where it contribute to

• The other barriers for current therapeutic drug regimens do not fully eradiate the virus from cellular and anatomical reservoirs. In certain cases patient requires to take daily pills which produce patient adherence. These agents have

• Current drug therapy can lower the systemic viral load below the detection limit therefore on discontinuation of treatment, there is relapse of the infection occur from the reservoir sites and a potential for resistance develops.

• Microbubbles-based drug delivery systems produce complete eradication of

• Micro bubbles containing antiretroviral drugs bind to the CD4+ T cells and macrophages, and reach to latent reservoir of CNS, the cerebrospinal fluid, the lymphatic system, tests, liver, kidney, lungs, the gut and in the macrophage.

• Microbubble-based drug delivery systems deliver antiretroviral drugs in vitro

• Microbubbles have average size less than that of red blood cell so it get pen-

• Microbubbles can generate strong signal so lower dose of intravenous required

• Gene therapy remove HIV completely from infected cells, as shown by reductions in the cells' overall rate of HIV production. Gene-editing technique.

• Gene therapy based on siRNA has shown promise for HIV/AIDS treatment. Microbubbles platforms for delivery of siRNA for HIV/AIDS treatment are in

their early stages but recent work has been met with optimism.

etrated into the small blood capillaries and releasing the drug.

• Microbubbles are used as tool for gene delivery.

the generation of elusive mutant viral genotypes

side effect and in some patient resistance develops.

Microbubbles-based drug delivery for HIV/AIDS treatment

viral load from the reservoir sites.

Microbubble as therapeutic agents

and also used in angiogenesis.

Gene therapy for HIV/AIDS treatment

Barriers of HIV/AIDS treatment

necessary duration.

macrophage.

and in vivo.

**9. Conclusion**

**110**


Microbubble used as preventive HIV/AIDS Vaccine

